The phase III PROfound trial is a head-to-head comparison of the PARP inhibitor olaparib with investigator’s choice of abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Participants are required to have progressed on a new hormonal agent and to harbor a tumor mutation in one of 15 genes involved in the homologous recombination repair pathway, such as BRCA1/2 and ATM.
The initial findings of the trial were presented at the ESMO Congress 2019. Olaparib significantly improved radiographic progression-free survival in men with mCRPC harboring mutations in DNA damage response and repair genes, compared with enzalutamide or abiraterone plus prednisone.
Eleni Efstathiou explains why the PROfound trial of the PARP inhibitor olaparib is the first step towards treating mCRPC in a more precise way (3:09):